Fluid Responsiveness Prediction During Prone Position

Acute Respiratory Distress Syndrome Clinical Trial

— PROLOAD  

Official title:

Evaluation of the Diagnostic Performance of 4 Dynamic Tests Evaluating Preload Dependence in Patients With Acute Respiratory Distress Syndrome in the Prone Position

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05898269
• Other study ID #: 69HCL23_0315
• Secondary ID: 2023-A00920-45
• Status: Recruiting
• Phase: N/A
• Start date: October 6, 2023
• Est. completion date: October 2026

Study information

• Verified date: January 2024
• Source: Hospices Civils de Lyon
• Contact: Laurent BITKER, Dr
• Phone: 4 26 10 94 93
• Email: laurent.bitker[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Predicting fluid responsiveness is primordial when caring for patients with circulatory shock as it allows correction of preload-dependent low cardiac output states, while preserving patients of the deleterious effects of excessive fluid resuscitation.

Patients with severe acute respiratory distress syndrome (ARDS) treated with prone positioning (PP) are a specific subset of patients, as 1) they frequently present with shock; 2) excessive fluid administration may lead to respiratory worsening due to increased hydrostatic oedema with potential subsequent worse clinical outcome; and 3) all available dynamic tests evaluating fluid responsiveness can only be performed in patients in the supine condition (which in the case of severe ARDS patients in PP occurs only for 8h over 24h). These elements warrant the development of specific tests allowing the clinician to predict fluid responsiveness with enough exactitude when caring for these patients.

We hypothesize that there exists diagnostic heterogeneity in the predictive performance of 4 clinical tests to identify fluid responsiveness in ARDS patients in PP. For the matter of this study, these 4 tests are the Trendelenburg maneuver, the end-expiratory occlusion test, the end-expiratory occlusion test associated with the end-inspiratory occlusion test, and the tidal volume challenge. The diagnostic reference of the study will be the relative change in cardiac index measured by transpulmonary thermodilution before and after a 500 ml fluid bolus, and will allow the adjudication of patients as being fluid responsive or not.

The primary objective of the study is to determine the area under the ROC curve of each of the 4 tests, with their respective 95% confidence interval.

All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus. Patients will only participate once. The expected duration of study participation is 30 minutes maximum.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: October 2026
• Est. primary completion date: October 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• adult patient (including patient under protective measures/wardship)

• with ARDS as defined by the Berlin criteria

• in the prone position as per international guidelines

• with a calibrated continuous cardiac output monitoring device

• with a clinical indication for a fluid bolus as prescribed by the clinician in charge, and fulfilling at least 2 clinical criteria: mottles, tachycardia, hypotension, drop in cardiac output, oliguria, high arterial lactate concentration, or any other detailed criterion

• with no respiratory efforts

Exclusion Criteria:

• acute cor pulmonale

• patient treated with veno-venous extra-corporeal membrane oxygenation

• hemorrhagic shock

• Child-Pugh C cirrhosis

• death expected to occur in less than 24h

• decision to withhold or suspend active treatments

• intracranial hypertension

• lower limb amputation

• obstruction of the inferior vena cava

• acute abdominal syndrome

• absence of consent to participate

• pregnancy

• patient previously enrolled in the same study

• lack of affiliation to a social security regimen, as per French legislation

• patient deprived of its liberty

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Syndrome

Intervention

Diagnostic Test:
• Trendelenburg maneuver
Bed tilting from the +13° position to the -13° position for 60 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the highest value observed during the maneuver
• End-expiratory occlusion test (EE OCC)
End-expiratory pause performed on the ventilator, and maintained for 15 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause
• End-expiratory and end-inspiratory occlusion test (EI OCC)
End-inspiratory pause performed on the ventilator, and maintained for 15 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test).
• Tidal volume challenge
Increase in tidal volume set on the ventilator from 6 ml.kg-1 of predicted body weight, to 8 ml.kg-1 for 60 seconds. Evaluator: difference in the pulse pressure variation measured at 6 ml.kg-1 and at 8 ml.kg-1.
• Fluid bolus (reference diagnostic method)
After the 4 tests, the patient will receive a 500-ml fluid bolus of crystalloids in less than 15 minutes. Evaluator (reference method): cardiac index measured by transpulmonary thermodilution before and immediately after the fluid bolus. Patients with a relative change in cardiac index > 15% will be identified as being fluid responders, and the others as non-responders.

Locations

Country	Name	City	State
France	CHU Gabriel Montpied	Clermont-Ferrand
France	Hôpital de la Croix Rousse, Hospices Civils de Lyon	Lyon
France	CHU de Nice - l'Archet 1	Nice
France	CHU Nice - Pasteur 2	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the ROC curve (AUROC) of the evaluated tests.	The AUROC will be determined for each of the 4 clinical tests evaluated in this study. The reference method to define the AUROC to design the curve will be the fluid responsive status (responder vs. non-responder) as determined by the fluid bolus. For each test, the AUROC will be accompanied with its 95% confidence interval.	30 minutes
Secondary	Comparison of diagnostic performance of the evaluated tests.	For this outcome measure, the AUROCs will be determined as for the primary outcome measure. The AUROCs will be compared using the Delong's method, with adjustments for the repetition of measurements in a single patient.	30 minutes
Secondary	Diagnostic performance metrics of each test	Sensitivity, specificity, positive predictive value, negative predictive value and likelihood ratios of the evaluated tests, computed for the optimal diagnostic threshold determined using the Youden J index of the ROC curve. The optimal threshold will only be computed for AUROCs significantly different from 0.5.	30 minutes
Secondary	Weighted diagnostic performance of each test	Sensitivity, specificity, positive predictive value, negative predictive value and likelihood ratios of the evaluated tests, computed for the optimal diagnostic threshold determined using the Youden J index of the ROC curve, and adjusted using weighting based on the clinical tradeoff of the subsequent fluid bolus on hemodynamic benefit vs. the respiratory risk. The optimal threshold will only be computed for AUROCs significantly different from 0.5.	30 minutes
Secondary	Grey zone area of the optimal diagnostic threshold of each test	Determination of the boundaries of a grey zone around the value of the optimal threshold of each test, in which the diagnostic performance is deemed clinically insufficient (excessive misclassification risk due to lack of discrimination). The grey zone around the optimal threshold will only be computed for AUROCs significantly different from 0.5.	30 minutes